The anti-CD74 mAb milatuzumab has already been tested in Phase II studies (NCT00868478 and NCT00989586) for the treatment of chronic lymphocytic leukemia and in combination with the anti-CD20 mAb veltuzumab in relapsed and refractory B-cell non-Hodgkin’s lymphoma. The gene discussed is CD74; the disease is B-cell chronic lymphocytic leukemia.